Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Next Generation Tissue Biomarkers Market Growth From $3.42 Billion In 2026 To $5.5 Billion By 2030 At A CAGR Of 12.6%
The next generation tissue biomarkers market has experienced significant growth in recent years. It is anticipated to increase from $3.03 billion in 2025 to $3.42 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.9%. This historical growth can be ascribed to reliance on traditional histopathology techniques, limited biomarker identification methods, growing oncology research, increasing adoption of companion diagnostics, and early-stage investment in genomic and proteomic studies.
The next generation tissue biomarkers market size is projected to experience substantial expansion over the upcoming years, reaching $5.51 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. This projected increase during the forecast period is primarily driven by breakthroughs in next-generation sequencing technologies, the incorporation of AI-powered tissue analysis, the development of spatial biology platforms, increasing financial commitment to multi-omics research, and enhanced partnerships between pharmaceutical companies and academic institutions. Significant developments anticipated during this timeframe involve the broadened application of spatial biology and multi-omics strategies, a greater uptake of digital pathology and AI-driven analysis in diagnostic procedures, an escalating need for biomarkers in oncology and companion diagnostics, an expansion in drug discovery and development leveraging tissue biomarkers, and the incorporation of transcriptomic and metabolomic biomarkers for tailored precision medicine.
Get A Free Sample Report With In-Depth Market Insights:
Next Generation Tissue Biomarkers Market Growth Backed By Core Demand Fundamentals
The increasing need for personalized medicine is anticipated to propel the expansion of the next generation tissue biomarkers market moving forward. Personalized medicine defines a medical strategy that customizes treatment based on an individual’s genetic makeup, lifestyle, and environmental factors. Its adoption is on the rise due to continuous advancements in genomic technologies, which facilitate highly specific and individualized treatment approaches. This heightened demand for personalized medicine is spurring the development of next-generation tissue biomarkers, as they supply the precise and tailored information necessary to adapt treatments to each patient’s unique tissue profile. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a significant increase from 6 approvals in 2022. The 2023 approvals also encompassed seven cancer drugs and three for other diseases and conditions. Thus, the escalating demand for personalized medicine is a key driver for the expansion of the next generation tissue biomarkers market.
Next Generation Tissue Biomarkers Market Segmentation: How Does The Market Break Down By Category?
The next generation tissue biomarkers market covered in this report is segmented –
1) By Type: Genomic Biomarkers, Proteomic Biomarkers, Epigenetic Biomarkers, Transcriptomic Biomarkers, Metabolomic Biomarkers
2) By Technology: Immunohistochemistry, Next-Generation Sequencing, Mass Spectrometry (Ms)-Based Proteomics, Spatial Biology Platforms, Digital Pathology And Artificial Intelligence Analysis, Other Technologies
3) By Application: Oncology, Companion Diagnostics, Drug Discovery And Development, Neurology, Other Applications
4) By End Use: Hospitals And Reference Labs, Pharma And Biotech Companies, Academic And Research Institutes, Contract Research Organizations
Subsegments:
1) By Genomic Biomarkers: Single Nucleotide Polymorphisms, Copy Number Variations, Gene Fusions
2) By Proteomic Biomarkers: Protein Expression Levels, Post-Translational Modifications, Protein-Protein Interactions
3) By Epigenetic Biomarkers: Histone Modification Patterns, Chromatin Remodeling Biomarkers, Non-Coding Ribonucleic Acid Regulation
4) By Transcriptomic Biomarkers: Long Non-Coding Ribonucleic Acids, Circular Ribonucleic Acids, Alternative Splicing Variants
5) By Metabolomic Biomarkers: Lipid Profiles, Amino Acid Signatures, Organic Acids
Next Generation Tissue Biomarkers Market Growth Trends Reshaping The Competitive Landscape
Leading companies within the next generation tissue biomarkers market are prioritizing the creation of sophisticated solutions, including genomic-based diagnostic assays and sequencing solutions, aiming to improve the precision, rapidity, and individualized nature of cancer diagnosis and therapy. These genomic-based diagnostic assays and sequencing solutions involve methods and instruments designed to analyze genetic data to pinpoint biomarkers linked to diseases, thereby facilitating highly accurate and tailored diagnostic and therapeutic strategies. An illustrative example occurred in August 2024, when Illumina Inc., a US-based biotechnology firm, secured FDA approval for its TruSight Oncology Comprehensive test, accompanied by two companion diagnostics, intending to quickly connect cancer patients with appropriate targeted therapies. This particular test analyzes over 500 genes from a single tissue sample, allowing for accurate selection of treatments for a range of solid tumors. Furthermore, it automates the detection of biomarkers and is capable of 24/7 deployment, substantially shortening turnaround times and boosting clinical efficiency, thereby exemplifying a contemporary method for streamlining cancer diagnostics within a regulated environment.
Next Generation Tissue Biomarkers Market Competitive Overview And Top Companies
Major companies operating in the next generation tissue biomarkers market are Roche Diagnostics, Thermo Fisher Scientific Inc., LabCorp., Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Bio-Techne Corporation, Myriad Genetics Inc., NeoGenomics Laboratories Inc., Foundation Medicine Inc., NanoString Technologies Inc., PathAI Inc., Biocartis Group NV, Personalis Inc., Ultivue Inc., Indica Labs Inc., Strata Oncology Inc., Genialis Inc., Alida Biosciences Inc., Biofidelity Ltd.
View The Full Next Generation Tissue Biomarkers Market Report:
Next Generation Tissue Biomarkers Market Regional Outlook: Where Is Opportunity Concentrated?
North America was the largest region in the next generation tissue biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation tissue biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
